Acute Lymphoblastic Leukemia (ALL)

First (CR1)/ Second Remission (CR2)
- Autologous or Allogeneic
  - CCT5001
    - Phase I
    - CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/ Refractory B Cell Malignancies
    - PI: Mikios
    - Stanford
  - BMT338
    - Phase I
    - DonorGrafts DerivedFrom OrcaGraft w/GVHD
    - Prophylaxis in MA-aloHCT in Hematologic Malignancies
    - PI: Meyer
    - Pending

First (CR1) of Higher Remission
- Allogeneic
  - BMT326
    - Phase III
    - Haploidentical HSCT &ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy
    - PI: Johnson
    - Pending

High Risk First (CR1) Remission
- Haplo
  - BMT338
    - Phase I
    - DonorGrafts DerivedFrom OrcaGraft w/GVHD
    - Prophylaxis in MA-aloHCT in Hematologic Malignancies
    - PI: Meyer
    - Pending

- Allogeneic
  - BMT333
    - Phase III
    - Transplantation of NiCord vs Unmanipulated UmbilicalCordBlood in Hematological Malignancies
    - PI: Rezvani
    - Sponsor: Gamida Cell

KEY
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Optional Path
- Enrollment on Hold
- Immunotherapy